Moving up the league table

RNS Number : 8513E

Aberdeen New Dawn Invest Trust PLC

09 July 2019

 

Aberdeen New Dawn - Update research from QuotedData

9^th July 2019

Moving up the league table

Whilst the ongoing trade dispute between the US and China creates a strong headwind for the region, this more challenging time is playing to Aberdeen New Dawn (ABD)'s strengths. Its focus on high-quality companies is being rewarded and it is climbing the performance league table once again. It is striking that, despite ABD's improved relative performance and a low ongoing charges ratio (one of the lowest of its peers), ABD remains on one of the widest discounts versus its competitors.

Full research:

https://quoteddata.com/research/aberdeen-dawn-moving-league-table-2/

This research is also available free on our website www.quoteddata.com where you will also find news, performance data and factsheets on every London listed Investment Company. QuotedData writes and distributes research on a number of quoted companies, facilitates meetings between those companies and existing and potential investors and assists in raising additional capital where required.

NB: Marten & Co was paid to produce this note on Aberdeen New Dawn Investment Trust and it is for information purposes only. It is not intended to encourage the reader to deal in the security or securities mentioned in this report. Please read the important information at the back of this note. QuotedData is a trading name of Marten & Co Limited which is authorised and regulated by the FCA. Marten & Co is not permitted to provide investment advice to individual investors categorised as Retail Clients under the rules of the Financial Conduct Authority.

QUOTEDDATA
123a Kings Road | London SW3 4PL
Tel: [phone]

www.quoteddata.com | [e-mail] ews service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

 

END